So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these ...

boosted by strong demand for a new formulation of its blockbuster eye drug Eylea. The company also announced a new quarterly cash dividend and boosted its share-buyback program by $3 billion ...

As the company faces increasing competition for its flagship product Eylea, it continues to leverage its strong research and development capabilities to expand its pipeline and explore new growth ...

The Federal Circuit left in place a pair of orders blocking two competitors of Regeneron Pharmaceuticals Inc. from marketing biosimilar versions of its blockbuster eye-disease drug Eylea in a ...

Locals near a needle exchange site in a Bronx park are cheering a councilman’s proposal to require city health workers to collect hundreds of discarded syringes littering the ground. Oswald ...

Workers at “needle exchange” spots across the city may be forced to collect used drug syringes that end up as litter under a new bill unveiled Thursday. Council member Oswald Feliz’s new ...

The European Commission's decision on approval is expected in the second half of January 2025. Eylea is used to treat neovascular age-related macular degeneration and other severe retinal diseases.